Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes - PubMed (original) (raw)

Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes

George S Eisenbarth. Diabetes. 2010 Apr.

Abstract

The Banting Medal for Scientific Achievement Award is the American Diabetes Association's highest scientific award and honors an individual who has made significant, long-term contributions to the understanding of diabetes, its treatment, and/or prevention. The award is named after Nobel Prize winner Sir Frederick Banting, who codiscovered insulin treatment for diabetes.

Dr. Eisenbarth received the American Diabetes Association's Banting Medal for Scientific Achievement at the Association's 69th Scientific Sessions, June 5–9, 2009, in New Orleans, Louisiana. He presented the Banting Lecture, An Unfinished Journey—Type 1 Diabetes—Molecular Pathogenesis to Prevention, on Sunday, June 7, 2009.

PubMed Disclaimer

Figures

FIG. 1.

FIG. 1.

Hypothesized “primary” pathogenic trimolecular complex of the NOD class II presenting molecule: I-Ag7/insulin peptide amino acids B chain 9-23/TCR with TRAV5D-4*04.

FIG. 2.

FIG. 2.

Model of the development of type 1A diabetes highlighting chronic progressive nature of the disease. Modified and reprinted with permission from N Engl J Med 1986;314:1360–1368.

FIG. 3.

FIG. 3.

Extreme risk of islet autoimmunity and diabetes for DR3/4-DQ2/DQ8 siblings who share both HLA haplotypes identical by descent with proband sibling.

FIG. 4.

FIG. 4.

Results of genome-wide association studies in type 1 diabetes. Modified and reprinted with permission from N Engl J Med 2009;360:1646–1654.

FIG. 5.

FIG. 5.

nPOD pancreas 608 of cadaveric donor with long-term type 1 diabetes, showing lobular loss of β-cells. Picture provided by R. Gianani from nPOD Web site (

www.jdrfnpod.org

).

FIG. 6.

FIG. 6.

A subgroup of islet autoantibody–positive relatives with the highest levels of insulin autoantibodies showed delayed progression to diabetes when treated with oral insulin to induce mucosal tolerance.

Similar articles

Cited by

References

    1. Rewers A, Klingensmith G, Davis C, Petitti DB, Pihoker C, Rodriguez B, Schwartz ID, Imperatore G, Williams D, Dolan LM, Dabelea D: Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus in youth: the Search for Diabetes in Youth Study. Pediatrics 2008; 121: e1258– e1266 - PubMed
    1. Dahlquist G, Källén B: Mortality in childhood-onset type 1 diabetes: a population-based study. Diabetes Care 2005; 28: 2384– 2387 - PubMed
    1. Makinen VP, Forsblom C, Thorn LM, Waden J, Kaski K, Ala-Korpela M, Groop PH: Network of vascular diseases, death and biochemical characteristics in a set of 4,197 patients with type 1 diabetes (The FinnDiane Study). Cardiovasc Diabetologia 2009; 8: 54 - PMC - PubMed
    1. Tamborlane WV, Beck RW: Continuous glucose monitoring in type 1 diabetes mellitus. Lancet 2009; 373: 1744– 1746 - PubMed
    1. Garg SK, Kelly WC, Voelmle MK, Ritchie PJ, Gottlieb PA, McFann KK, Ellis SL: Continuous home monitoring of glucose: improved glycemic control with real-life use of continuous glucose sensors in adult subjects with type 1 diabetes. Diabetes Care 2007; 30: 3023– 3025 - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources